Michael DesJardin
Chief Tech/Sci/R&D Officer bij HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
Profiel
Momenteel bekleedt Michael A. DesJardin de functie van Executive VP-Technical Operations & Quality bij Horizon Therapeutics Plc en Senior Vice President-Technical Operations bij Horizon Pharmaceutical LLC (een dochteronderneming van Horizon Therapeutics Plc). Hij is ook Senior Vice President-Technical Operations bij Horizon Pharmaceutical LLC. Daarvoor bekleedde hij de functie van Senior Vice President Product Development bij Jazz Pharmaceuticals Plc en Executive Director-Implant Research & Development bij ALZA Corp. De heer DesJardin behaalde een bachelorgraad aan de Universiteit van Californië, Berkeley.
Actieve functies van Michael DesJardin
Bedrijven | Functie | Begin |
---|---|---|
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Chief Tech/Sci/R&D Officer | 01-02-2017 |
Eerdere bekende functies van Michael DesJardin
Bedrijven | Functie | Einde |
---|---|---|
RAPTOR PHARMACEUTICAL CORP | Chief Tech/Sci/R&D Officer | 01-10-2016 |
JAZZ PHARMACEUTICALS PLC | Corporate Officer/Principal | 01-03-2015 |
ALZA CORPORATION | Chief Tech/Sci/R&D Officer | - |
Opleiding van Michael DesJardin
University of California, Berkeley | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
JAZZ PHARMACEUTICALS PLC | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
ALZA Corp.
ALZA Corp. Pharmaceuticals: MajorHealth Technology ALZA Corp. provides drug delivery solutions and develops pharmaceutical products. The company applies its delivery technologies to develop pharmaceutical products with enhanced therapeutic value for its own portfolio and for many of the world's leading pharmaceutical companies. The company was founded by Martin Gerstel and Alejandro Zaffaroni in 1968 and is headquartered in Vacaville, CA. | Health Technology |
Horizon Therapeutics Plc
Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
Horizon Pharmaceutical LLC
Horizon Pharmaceutical LLC Pharmaceuticals: MajorHealth Technology Horizon Pharmaceutical LLC engages in the development of transformative treatments for people affected by rare and debilitating diseases. It offers PROCYSBI, a delayed-release capsule, which is used for the management of nephropathic cystinosis in adults and for six years and older children. The company was founded by Christopher M. Starr and Todd C. Zankel on April 29, 2002 and is headquartered in Novato, CA. | Health Technology |